June 16, 2016
PeptiDream, a spin-out of the University of Tokyo, said on June 15 that a lead macrocyclic compound, identified by the company and optimized by its partner Bristol-Myers Squibb, has entered into clinical development. It is the first compound in PeptiDream’s...read more